Page 1 of 39
Epidemiological and clinical studies have reported an association between leukocyte telomere length (LTL) and Alzheimer’s disease (AD). However, genetic association between the two phenotypes remains largely u...
Exploring the early stages of Alzheimer's disease (AD) is crucial for timely intervention to help manage symptoms and set expectations for affected individuals and their families. However, the study of the ear...
Mild cognitive impairment (MCI) is a heterogeneous disorder with significant individual variabilities in clinical and biological features. Abnormal inter-regional structural covariance suggests disruption of t...
Hyperexcitability in Alzheimer’s disease (AD) is proposed to emerge early and contribute to disease progression. The dentate gyrus (DG) and its primary cell type, granule cells (GCs) are implicated in hyperexc...
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder clinically characterized by memory decline, cognitive dysfunction, language impairment, deterioration of visuospatial skills, and p...
Depression serves as a prodromal symptom of dementia, and individuals with depression exhibit a significantly higher risk of developing dementia. The aim of this study is to develop and validate a novel dement...
Oxysterols, gut metabolites, and N6-methyladenosine (m6A) are extensively implicated in the pathogenesis of cognitive dysfunction, while their alterations in different stages of mild cognitive impairment (MCI)...
Cognitive frailty (CF) in older adults is a potentially reversible syndrome that may benefit from lifestyle-based multidomain interventions. This study assessed the AGELESS intervention’s impact on cognitive, ...
The SorLA protein, encoded by the Sortilin-related receptor 1 (SORL1) gene, is a major player in Alzheimer’s disease (AD) pathophysiology. Functional studies demonstrated that SorLA deficiency results in increase...
Onset-predictive biomarker tests (OPBT) in genetic frontotemporal dementia (FTD) may be used to recruit mutation carriers into preventive clinical trials before symptoms manifest. This would require disclosure...
The pathological effects of amyloid β oligomers (Aβo) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimer’s disease (AD). Positron emission tom...
Emerging evidence supports the diagnostic and prognostic utility of plasma biomarkers in Alzheimer’s disease (AD), particularly in early disease stages. We sought to extend these findings by evaluating the pro...
Mutations in the presenilin 1 gene (PSEN1) are well-known causes of early-onset familial Alzheimer’s disease, but they can also present with atypical phenotypes such as pure spastic paraparesis. This study aims t...
The ubiquitin-proteasome system (UPS) is responsible for most protein degradation and its malfunction is normally observed in neurodegenerative diseases, including Alzheimer’s disease (AD). The autocrine motil...
Emerging evidence implicates early dysfunction of dopaminergic neurons in the Ventral Tegmental Area (VTA) as a key contributor to Alzheimer’s Disease (AD) pathophysiology. Specifically, the VTA dopaminergic n...
In Alzheimer’s disease (AD), MRI atrophy patterns can distinguish between amnestic (typical) and non-amnestic (atypical) clinical phenotypes and are increasingly used for diagnosis and outcome measures in clin...
A recent paper published a lecanemab analysis with data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. While the authors mention the limitations of F...
Both aging and Alzheimer's disease (AD) affect brain networks, with early disruptions occurring in regions involved in episodic memory. Few studies have, however, focused on distinguishing region-specific effe...
White matter hyperintensity (WMH) is a key feature of cerebral small vessel disease (CSVD). The impact of the choroid plexus (CP) volume on disease progression remains largely unexplored. This study evaluated ...
The concept of metabolic syndrome (MetS) was developed to identify individuals at higher risk of type 2 diabetes and cardiovascular disease, but its relevance for dementia remains unclear. We examined MetS in ...
Cognitive resilience (CR) contributes to the variability in risk for developing and progressing in Alzheimer’s disease (AD) among individuals. Beyond genetics, recent studies highlight the critical role of lif...
The original article was published in Alzheimer's Research & Therapy 2025 17:45
The association between obesity and young-onset dementia (YOD, defined as dementia diagnosed before age 65) is established, but the specific impact of abdominal obesity in women remains unclear. Abdominal obes...
Dementia risk is significantly shaped by cardiovascular health, with elevated blood pressure emerging as a key risk factor for adverse brain aging. Blood biomarkers such as pTau181, Aβ42/40, NfL, and GFAP have...
Long-term therapy with nucleos(t)ide analogs (NUCs) is inevitable for chronic hepatitis B (CHB) patients. However, how NUC therapy on the developing Alzheimer’s disease (AD) in these patients remains controver...
The original article was published in Alzheimer's Research & Therapy 2025 17:49
Subjective cognitive concerns (SCC) have emerged as important early indicators of Alzheimer’s disease (AD) risk. Traditional measures of SCC rely on recall-based assessments, which may be limited in capturing ...
Beta-synuclein (β-syn), measured at N-terminal epitopes, is an emerging cerebrospinal fluid (CSF) biomarker for synaptic degeneration in Alzheimer's disease (AD). Targeting the mid-region or C-terminus of β-sy...
The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into tradition...
Longitudinal subtypes in Alzheimer’s disease (AD) have been identified based on their distinct brain atrophy trajectories, encompassing mediotemporal and cortical pathways. These subtypes include minimal atrop...
Alzheimer’s Disease (AD) is characterized by progressive declines in cognitive and motor functions, impairing daily activities. Traditionally, AD diagnosis relies on cognitive assessments, but emerging evidenc...
In this article, we have carefully read the author’s comments on our published article regarding the post-marketing safety concerns of lecanemab based on the Food and Drug Administration Adverse Event Reportin...
Disruptions in circadian rhythms are commonly observed in patients with Alzheimer’s disease (AD) and could potentially accelerate the progression of the condition. However, the relationship between circadian r...
Sleep disturbances have been associated with an increased risk of dementia. The mechanisms remain unclear, although neurodegenerative and vascular pathways are potentially involved. Hence, our study aims to in...
Cognitive decline is a condition affecting almost one sixth of the elder population and is widely regarded as one of the first manifestations of Alzheimer’s disease. Despite the extensive body of knowledge on ...
Tau pathology in Alzheimer’s disease (AD) propagates trans-synaptically along structurally connected brain networks and in synergy with amyloid pathology it induces synaptic damage. However, the in vivo relati...
Alzheimer’s disease (AD) is a neurodegenerative disease. Amyloid β-protein (Aβ) is one of the key pathological features of AD, which is cytotoxic and can damage neurons, thereby causing cognitive dysfunction. ...
Ethnic variations and detection methods may lead to differences in diagnostic biomarkers of dementia, and few comparative studies have evaluated the six plasma biomarkers of Alzheimer’s disease (AD) and other ...
Although interactions between amyloid-beta and tau proteins have been implicated in Alzheimer's disease (AD), the precise mechanisms by which these interactions contribute to disease progression are not yet fu...
Personalized repetitive transcranial magnetic stimulation (rTMS) of the precuneus (PC) is emerging as a new non-invasive therapeutic approach in treating Alzheimer’s disease (AD).
Plasma biomarkers for Alzheimer's disease (AD) are a promising tool for accessible and accurate biological diagnostics. However, data in clinical practice are needed to better understand their diagnostic and p...
Research has shown that sedentary behavior (SB) may increase dementia risk, but it remains unclear whether concentrated moderate to vigorous physical activity (MVPA) can compensate such negative effects. This ...
The formation and retrieval of episodic memory is dependent on the coordinated activity of multiple brain regions and neural networks, with the Papez circuit playing a critical role in this process. Recently, ...
We aimed to investigate the association between sleep apnea and incident dementia (dementia of the Alzheimer type [DAT] and vascular dementia) and whether differences in the effects of sleep apnea on dementia ...
The amygdala plays a role in behavior and emotional response and is vulnerable to Alzheimer’s disease (AD) pathology, yet little is known about amygdala tau accumulation before clinical symptom onset. To inves...
The original article was published in Alzheimer's Research & Therapy 2025 17:47
Alzheimer’s disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid-beta (Aβ) and neurofibrillary tangles. Recent studies emphasize the role of vascular factors, including t...
Preventing dementia and Alzheimer’s disease (AD) is a global priority. Multimodal interventions targeting several risk factors and disease mechanisms simultaneously are currently being tested worldwide under t...
Neurodegenerative diseases, such as Alzheimer’s disease (AD), pose a formidable global challenge. While therapeutic options are available, their limitations are significant, necessitating the development of in...
Nicotinamide, a form of B3 vitamin, is an NAD+ precursor that reduces pTau231 levels via histone deacetylase inhibition in murine models of Alzheimer’s disease (AD). A recent phase 2a randomized placebo-controlle...
Alzheimer's Research & Therapy